PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
Oncology·MeSH: Lung Neoplasms
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| acasunlimab | Genmab A/S (GMAB) |
Frequently asked questions
How many drugs are in development for PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC?
BioSniper tracks 1 drug in development for PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC across 1 company.
How many clinical trials target PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC?
There are 1 clinical trial targeting PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC tracked by BioSniper.
Deep-dive into PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis